Is There Still a Role for Intravenous Heparin in Acute Stroke?

Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?

“…9 It has been suggested that the failure of most clinical trials to demonstrate a benefit from heparins/heparinoids in acute stroke reflects discordance between patients in real life and those included in clinical trials. 9,10,12 In particular, there may be concern that certain subgroups, not adequately represented in clinical trials, may benefit from anticoagulant therapy. In this study, we hypothesized that the presence of clinical factors would be associated with a preferential response to LMWH.…”

Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?

“…9 It has been suggested that the failure of most clinical trials to demonstrate a benefit from heparins/heparinoids in acute stroke reflects discordance between patients in real life and those included in clinical trials. 9,10,12 In particular, there may be concern that certain subgroups, not adequately represented in clinical trials, may benefit from anticoagulant therapy. In this study, we hypothesized that the presence of clinical factors would be associated with a preferential response to LMWH.…”

Determinants of IV heparin treatment in patients with ischemic stroke

“…[1][2][3][4] Wide variation in the use of this treatment between physicians and between institutions was reported 15 years ago. The IV administration of UFH in patients with acute ischemic stroke is controversial.…”

“…2,3 The gender difference cannot be explained by age, stroke type, or severity. Patients who had one or more condition that is generally accepted to have an "embolic risk" had a strong and significantly increased chance of being treated with IV heparin, perhaps reflecting the position of the treatment's advocates.…”

Impact of Guidelines on Clinical Practice

“…2,3 The main rationale for emergent administration of intravenous heparin in patients with acute stroke have included prevention of neurological worsening or recurrent embolization. Intracranial hemorrhage and systematic bleeding are significant adverse events associated with such therapy.…”

Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?

“…9 It has been suggested that the failure of most clinical trials to demonstrate a benefit from heparins/heparinoids in acute stroke reflects discordance between patients in real life and those included in clinical trials. 9,10,12 In particular, there may be concern that certain subgroups, not adequately represented in clinical trials, may benefit from anticoagulant therapy. In this study, we hypothesized that the presence of clinical factors would be associated with a preferential response to LMWH.…”

Determinants of IV heparin treatment in patients with ischemic stroke

“…[1][2][3][4] Wide variation in the use of this treatment between physicians and between institutions was reported 15 years ago. The IV administration of UFH in patients with acute ischemic stroke is controversial.…”

“…2,3 The gender difference cannot be explained by age, stroke type, or severity. Patients who had one or more condition that is generally accepted to have an "embolic risk" had a strong and significantly increased chance of being treated with IV heparin, perhaps reflecting the position of the treatment's advocates.…”

Impact of Guidelines on Clinical Practice

“…2,3 The main rationale for emergent administration of intravenous heparin in patients with acute stroke have included prevention of neurological worsening or recurrent embolization. Intracranial hemorrhage and systematic bleeding are significant adverse events associated with such therapy.…”

Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?

“…9 It has been suggested that the failure of most clinical trials to demonstrate a benefit from heparins/heparinoids in acute stroke reflects discordance between patients in real life and those included in clinical trials. 9,10,12 In particular, there may be concern that certain subgroups, not adequately represented in clinical trials, may benefit from anticoagulant therapy. In this study, we hypothesized that the presence of clinical factors would be associated with a preferential response to LMWH.…”

Determinants of IV heparin treatment in patients with ischemic stroke

“…[1][2][3][4] Wide variation in the use of this treatment between physicians and between institutions was reported 15 years ago. The IV administration of UFH in patients with acute ischemic stroke is controversial.…”

“…2,3 The gender difference cannot be explained by age, stroke type, or severity. Patients who had one or more condition that is generally accepted to have an "embolic risk" had a strong and significantly increased chance of being treated with IV heparin, perhaps reflecting the position of the treatment's advocates.…”

Impact of Guidelines on Clinical Practice

“…2,3 The main rationale for emergent administration of intravenous heparin in patients with acute stroke have included prevention of neurological worsening or recurrent embolization. Intracranial hemorrhage and systematic bleeding are significant adverse events associated with such therapy.…”